21 results about "Alpha-fetoprotein" patented technology

A clinical decision support device, comprising: a parameter acquisition module, configured to acquire measured values for markers in a biomarker combination of a subject, wherein the biomarker combination at least comprises an alpha fetoprotein, an abnormal prothrombin, γ-glutamyltransferase, and an albumin; a risk assessment module, configured to input the measured values for the markers in the biomarker combination into a calculation model to obtain an output of the calculation model as a liver cancer risk prediction result of the subject; and an output module, configured to output the liver cancer risk prediction result of the subject. Also disclosed are a sample analysis system and a method for assessing a liver cancer risk of a subject, capable of better assessing a liver cancer risk of a subject.

The invention provides a living cell surface double-tumor marker in-situ detection method based on a closed bipolar electrode (cBPE) array and an electrochemiluminescence (ECL) technology. The living cell surface double-tumor marker in-situ detection method is used for synchronously quantifying carcino-embryonic antigen (CEA) and alpha-fetoprotein (AFP). According to the system, the high specific surface area, the ordered porous structure and the rich surface amino active sites of a covalent organic framework (COF) material are utilized, and the excellent conductivity and biocompatibility of gold nanoparticles (Au NPs) are combined, so that the bifunctional signal probe COF (at) Au (at) MBApt is constructed. The probe can simultaneously load a large number of signal molecule methylene blue (MB) and is coupled with a targeting aptamer (Apt), so that high-capacity labeling and specific recognition of a target marker are realized.

The application relates to a preparation method and application of a ternary heterojunction composite photoelectrochemical immunosensor, and belongs to the technical field of photoelectrochemical biosensors, and particularly relates to a preparation method and application of a photoelectrochemical immunosensor for detecting alpha-fetoprotein by adopting a BiPO4 / BiOBr / CdS composite material. The method is characterized in that a ternary heterojunction is assembled on an FTO modified electrode to fix a capture antibody, and the accurate determination of alpha-fetoprotein is realized through a photocurrent signal response. The BiPO4 / BiOBr heterojunction expands the forbidden band width and expands the light absorption range; due to the sensitization of CDs, the absorption of visible light is enhanced, so that the photocurrent signal is increased. The method has the advantages of good stability, strong specificity, high sensitivity, good reproducibility and the like, is good for the rapid detection of alpha-fetoprotein, solves the existing technical difficulties, and provides a feasible method for the detection of tumor markers.

A system for generating a hepatocellular carcinoma (HCC) report for a subject based on blood-based molecular profiling is provided. The system includes a sample preparation module configured to process a blood sample by isolating both plasma and serum fractions. A nucleic acid extraction module extracts a microRNA (miRNA) profile from the plasma fraction, and a real-time PCR module detects and quantifies the expression levels of a predefined panel of miRNAs, including miR-361-5p, miR-130a-3p, miR-27a-3p, miR-30d-5p, and miR-193a-5p. The expression levels of the predefined panel of miRNAs are used by a trained machine learning classifier to generate a HCC risk classification categorizing the subject into one of HCC risk levels. An alpha-fetoprotein (AFP) level detected and quantified from the serum fraction may also be used in combination with the miRNA expression levels in the HCC risk classification for enhanced prediction accuracy.

The invention belongs to the technical field of alpha fetoprotein visual quantitative analysis, and particularly relates to a visual quantitative analysis method for alpha fetoprotein in saliva, a double-recognition multiple-quenching molecular imprinting and electrochemical luminescence microscope is constructed, and MI-ECLM takes self-developed SECLM as a signal output device and comprises a molecular imprinting polymer and a double-mechanism quencher; preparing a saliva sample and performing pretreatment; the pretreated saliva sample is placed on an MI-ECLM sensor, and an optical image is obtained through electrochemical luminescence imaging; and analyzing the optical image to realize visual quantitative detection of alpha fetoprotein in saliva.

The invention discloses an intelligent prediction system and method for early recurrence risk after liver cancer thermal ablation, and aims to solve the technical problem that prediction is not timely and inaccurate due to the fact that an existing prediction model ignores intraoperative dynamic information. According to the method, dynamic time sequence data such as tissue impedance and power in the thermal ablation process are collected in real time, and preoperative static data such as tumor size and alpha fetoprotein level are combined, so that a double-branch fusion prediction model is constructed. The model comprises a time sequence processing branch used for learning dynamic data time dependence and a static processing branch used for extracting static data features. By fusing the features of the two branches, the model can output a probability value representing the postoperative early recurrence risk. According to the method and the system, instant accurate risk stratification after operation is realized, and further, intraoperative intervention can be guided through real-time feedback, so that the early recurrence risk is actively reduced, and the prognosis of a patient is improved.

This invention provides a nanocomposite material, its preparation method, and its application in a sandwich-structured enhanced immunosensor, belonging to the field of biosensor technology. This invention synthesizes a Ru@SiO2-NH2-Au nanocomposite material using a chemical oxidation method, constructs a Fe3O4@SiO2-NH2 composite carrier as a sensing platform, and successfully achieves ultrasensitive ECL immunosensor detection. The separation and enrichment of Fe3O4 during the sensing process improves detection efficiency. The -NH2 functional groups modified on the SiO2 surface provide active sites for the immobilization of the nanocomposite material and the specific recognition and binding of alpha-fetoprotein (AFP), achieving a highly efficient "carrier-functional material-target biomarker" interaction. This ECL immunosensor can detect AFP with high sensitivity, exhibiting a linear relationship within the range of 97.0% to 103.6%, with a detection limit of 1.28 × 10⁻⁶. ‑13 mg·mL ‑1 This provides a valuable reference for the future development of other AFP sensors.

The present invention relates to a composition for diagnosing, detecting, or monitoring a liver cancer disease, comprising nucleic acid affinity ligands and / or peptide affinity ligands for a group of biomarkers comprising at least Prolactin, Alpha Fetoprotein (AFP) and Interleukin-6 (IL-6) and, optionally, further comprising one or more of Squamous Cell Carcinoma Antigen (SCC), Metallopeptidase Inhibitor 1 (TIMP-1) and CYFRA 21-1. The present invention further envisages corresponding methods for diagnosing, detecting or monitoring a cancer disease in a subject, as well as a computer-implemented method for the analysis of a sample of a subject, a computer-implemented method for providing a trained machine learning model, the use of affinity ligands for detecting, diagnosing, or monitoring a liver cancer disease, in particular early forms of liver cancer.

The invention belongs to the technical field of liver disease diagnosis, and particularly relates to a biomarker for auxiliary diagnosis of liver diseases and application, the biomarker comprises serum phosphatidylcholine, and further comprises any one or two of alpha fetoprotein and chitosanase 3-like protein 1. As a newly discovered liver disease diagnosis index, the PC provided by the invention has the highest predictive ability in hepatitis and higher predictive ability in liver cirrhosis and liver cancer, can improve the predictive ability of other indexes on liver diseases, and has very high clinical value.

The invention discloses construction and application of a bifunctional biosensor based on coordination induced enhancement and interface antifouling, and belongs to the technical fields of light / electrochemistry, biochemical analysis and nano science. According to the invention, tris (4, 4 '-dicarboxylic acid-2, 2'-dipyridyl) ruthenium is used as a ligand, and Zn / Ru-MOF with a coordination induction enhancement effect is prepared and is used as a luminous body. Due to effective aggregation of the ligand and energy transfer from Zn < 2 + > to the ligand, Zn / Ru-MOF has high ECL efficiency. Besides, Zn / Ru-MOF is modified with 3-aminopropyl dimethylamine zwitterions to serve as a sensing substrate, so that interface adsorption of interfering substances is resisted, and integration of self-enhanced luminescence and interface antifouling is realized. Based on pairing of a complementary chain and an aptamer chain, a significant "signal-off" is achieved through resonance energy transfer. The quenching probe is released according to the competitive mechanism of the target, resulting in signal recovery. Based on this, the constructed biosensor shows a low detection limit, and shows a huge application potential in clinical monitoring of alpha fetoprotein in a complex serum medium.

The invention provides a system for detecting hepatocellular carcinoma micro-RNA (Ribonucleic Acid) based on blood molecular spectrum analysis. The system includes a sample preparation module for processing a blood sample of a subject and separating a plasma portion and a serum portion therefrom. And the nucleic acid extraction module is used for extracting the microRNA expression spectrum from the plasma part. The real-time polymerase chain reaction module is used for detecting and quantifying the expression quantity of the micro RNA group in the micro RNA expression spectrum, and the real-time polymerase chain reaction module comprises miR-361-5p, miR-130a-3p, miR-27a-3p, miR-30d-5p and miR-193a-5p. Processing by a trained classifier according to the quantitative result to generate a hepatocellular carcinoma risk classification result so as to grade the subjects according to the hepatocellular carcinoma risk; and the trained classifier processing can be further incorporated into a result generated by combining the alpha fetoprotein expression quantity detected and quantified from the serum part with the expression quantity of the microRNA group, so that the accuracy is improved.

The present application relates to a kind of preparation method of redox probe based on metal organic framework derived nanosheet and its product and application, belong to the technical field of preparation of redox probe.The present application is mainly to form super-thin metal organic framework material by self-assembly of metal ion (Cu 2+ Or Co 2+ ) and organic ligand, continue to react with ascorbic acid (AA), chloroauric acid (HAuCl4) to obtain metal-UMOFNs@Au NPs, then mixed with alpha-fetoprotein antibody (anti-AFP), carcinoembryonic antibody (anti-CEA) and glucose oxidase (GOD) after incubation to obtain redox probe (metal-UMOFNs@Au NP-Ab2-GOD).In addition, the redox probe prepared by the present application can be used to prepare sandwich-type electrochemical immunosensor capable of simultaneously detecting CEA and / or AFP, and the immunosensor has higher sensitivity, good selectivity and stability.

The present invention relates to a method for providing information necessary for the diagnosis of liver cancer by measuring the percentage of fucosylated AFP (AFP-Fuc%). In the present invention, AFP present at a low concentration in serum is quantified with excellent sensitivity by performing direct mass spectrometry on total fucosylated AFP without glycan removal or the use of antibodies or lectins that recognize fucosylation sites, and hepatocellular carcinoma is detected with significantly improved accuracy compared to conventional GALAD scores using Lens culinaris agglutinin-reactive fraction (AFP-L3) as a marker. In particular, the present invention can be effectively used to establish treatment strategies early and improve patient survival rates by distinguishing early hepatocellular carcinoma from common non-tumor liver diseases with high reliability.

This invention discloses an ultrasensitive and rapid sensor for detecting alpha-fetoprotein (AFP), constructed based on a sandwich immunoassay structure and the electrochemiluminescence resonance energy transfer (ECL-RET) principle. The advantages of this invention compared to existing technologies are: high sensitivity and ultra-low detection limit: This invention innovatively uses MIL-NH2-RuMOF@Pt as an energy donor, whose MOF structure can load a large amount of Ru(bpy)3. 2+ The luminescent molecule provides a strong and stable initial ECL signal; ZnO@PDA acts as the acceptor, with its absorption spectrum highly overlapping with the donor emission spectrum, and PDA modification improves biocompatibility and coupling efficiency. The highly efficient RET pair formed by these two molecules, combined with the sandwich immunoamplification effect, achieves efficient signal quenching, resulting in a detection limit as low as 1.1 × 10⁻⁶. ‑ 14 mg·mL⁻¹; wide linear range; excellent specificity and accuracy; good stability and repeatability; broad application prospects.

This application relates to a clinical decision support device, comprising: a parameter acquisition module configured to acquire the measured values ​​of each biomarker in a biomarker combination of a subject, wherein the biomarker combination includes at least alpha-fetoprotein, abnormal prothrombin, gamma-glutamyl transferase, and albumin; a risk assessment module configured to input the measured values ​​of each biomarker in the biomarker combination into a computational model, and obtain the output of the computational model as a liver cancer risk prediction result for the subject; and an output module configured to output the liver cancer risk prediction result for the subject. This application also relates to a sample analysis system and a method for assessing the liver cancer risk of a subject. This application enables improved assessment of the liver cancer risk of a subject.

The invention discloses a preparation method of a photoelectrochemical biological aptamer sensor for detecting alpha fetoprotein based on a binary doped composite material, and relates to a preparation method of a photoelectrochemical biological aptamer sensor for detecting alpha fetoprotein. The technical problems that an existing electrochemical biosensor for detecting alpha fetoprotein is low in sensitivity, narrow in detection range, low in detection speed and poor in stability are solved. The preparation method comprises the following steps: 1, preparing TiO2 NRA / FTO; (2) preparing a Sn-TiO2 NRA / FTO electrode; (3) preparing a BiVO4 / Sn-TiO2 NRA / FTO (fluorine-doped tin oxide) electrode; and 4, preparing the photoelectrochemical biological aptamer sensor. The linear detection range of alpha fetoprotein detected by the sensor is 0.001 ng / mL-500 ng / mL, the detection limit is as low as 0.75 ng / mL, and excellent gt is shown; the method has long-term stability in 850 seconds, low detection limit and short detection time, and can be used in the field of alpha fetoprotein detection.

The application belongs to the technical field of medical diagnosis, and discloses a marker for evaluating the curative effect of TACE combined with sindibimab and bevacizumab in treating hepatocellular carcinoma and a construction method and application of a FAAP prognosis scoring model. The application develops and verifies a FAAP prognosis scoring system, a new type of composite model integrating four indexes of fibrin degradation product / cholinesterase ratio x 1000 (FCR), aspartate aminotransferase (AST), alpha-fetoprotein (AFP) and portal vein tumor thrombus (PVTT), for predicting the survival of uHCC patients receiving TACE-sindibimab-bevacizumab triple therapy. The tool has instant clinical value, can optimize patient selection, guide adaptive treatment upgrade, and provide a standardized efficacy evaluation basis for exploring the clinical trials of TACE-immunotherapy-anti-angiogenesis combined schemes.

This invention relates to the field of medical reagent kit technology, and discloses a combined detection kit for microRNA and alpha-fetoprotein, comprising reagent one and reagent two. Reagent one includes: reverse transcriptase mixture, reverse transcription buffer, dilution buffer, amplification detection solution 1, amplification detection solution 2, amplification detection solution 3, amplification detection solution 4, positive control, negative control, blank control, and a value card; reagent two includes: labeled antibody, coating antibody, calibrator 1, calibrator 2, calibrator dilution buffer, washing buffer, and substrate solution. This invention provides an integrated kit that combines the analysis of three specific microRNAs (miR-21, miR-125a, miR-150) in serum extracellular vesicles, a stable internal control (miR-16), and serum AFP concentration to generate a comprehensive score (E-value), significantly improving the sensitivity and specificity of HCC auxiliary diagnosis and solving the problem of poor diagnostic performance of single indicators.

This invention relates to the field of biomedical technology, and in particular to a T-cell receptor targeting the AFP peptide, its preparation method, and a companion diagnostic kit. A T-cell receptor targeting the AFP peptide, wherein the sequence of the AFP peptide is FMNKFIYEI, and the T-cell receptor contains a TCRα chain variable domain and a TCRβ chain variable domain, is provided. The corresponding nucleic acid molecule, vector, and host cell are provided, as well as a method for preparing the T-cell receptor. A companion diagnostic kit containing the cell receptor is further provided. This invention provides a better option for companion diagnostic and therapeutic products for alpha-fetoprotein (AFP) cells.

The invention belongs to the technical field of biosensor preparation, and relates to a preparation method of a lactic acid and alpha fetoprotein detection biosensor. The preparation method comprises the following steps: adding single-layer graphene oxide into N, N-dimethylformamide, uniformly mixing, adding polyacrylonitrile, uniformly mixing, and adding dopamine hydrochloride to obtain a spinning solution; and after spinning with the spinning solution, drying in a vacuum drying oven, and then fixing on a gold electrode to obtain an electrode P. And uniformly mixing lactate oxidase and chitosan, dropwise adding the mixture to the surface of the electrode P, dropwise adding an antibody solution after drying, and performing secondary drying to obtain the sensing electrode. The nanofiber membrane with proper pore diameter and fiber diameter is regulated and controlled, is used for preparing a sensor for simultaneously detecting lactic acid and alpha fetoprotein, and has higher performance in detection of a real sample. The detection range of lactic acid and alpha fetoprotein is wide, the preparation process is simple, the cost is low, and the method can be used for large-scale production.